Anis Rauf, DO
Nephrology · Hinsdale, ILNPI 1639259740
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $323,739 of the $452,837 with a category attached, or 71.5%. It is spread thinly across 44 manufacturers, the largest accounting for just 21.1%. Reporting peaked in 2021 at $117,918 and has fallen 70.2% since, to $35,163 in 2025. Among nephrology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,005 payments — averaging $450.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$96K
- AstraZeneca$75K
- Bayer$60K
- OPKO Pharmaceuticals, LLC$59K
- GSK$46K
- Daiichi Sankyo Inc.$42K
- plus $75K from 38 others
What the payments were for
- Consulting fees$23,7105%
- Speaking & faculty fees$323,73971%
- Travel & lodging$71,31216%
- Food & beverage$33,3837%
- Education$6440%
- Entertainment$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$94,119
- Kerendia$58,540
- Rayaldee$58,295
- BENLYSTA$44,333
- LOKELMA$43,523
- INJECTAFER$41,660
- PURIFIED CORTROPHIN GEL$32,162
- FARXIGA$29,290
- (815) Thiola$12,286
- Parsabiv$10,000
- KRYSTEXXA$950
- INVOKANA$750
- Renal - CRRT$630
- ACTHAR$378
- JYNARQUE$313
- Envarsus$232
- IBSRELA$225
- GVOKE PFS$168
- LUPKYNIS$145
- Watchman$138
How this compares
$452,837 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 14 | $893,336 |
| Thiola EcTiopronin | 13 | $103,371 |
| RayaldeeCalcifediol | 37 | $64,435 |
| FarxigaDapagliflozin Propanediol | 50 | $57,257 |
| XphozahTenapanor Hcl | 13 | $47,172 |
| LokelmaSodium Zirconium Cyclosilicate | 49 | $42,836 |
| VelphoroSucroferric Oxyhydroxide | 16 | $39,630 |
| AuryxiaFerric Citrate | 14 | $29,499 |
| JardianceEmpagliflozin | 20 | $25,286 |
| Sevelamer Carbonate | 61 | $8,401 |
| Nifedipine ErNifedipine | 56 | $3,825 |
| Torsemide | 101 | $3,451 |
| Potassium Citrate ErPotassium Citrate | 14 | $2,243 |
| Potassium Chloride | 60 | $2,157 |
| Losartan Potassium | 105 | $1,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $75,497 | $100,09399 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $59,456 | $64,43537 claims |
| Fresenius USA Marketing, Inc.Velphoro | $38 | $39,63016 claims |
| Akebia Therapeutics IncAuryxia | $357 | $29,49914 claims |
| Boehringer IngelheimJardiance | $703 | $25,28620 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $33,596 | $26211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 524 nephrology providers in Illinois.
Other nephrology in Hinsdale
- Suneel UdaniHinsdale$336K
- Myles WolfChicago$2.1M
- Mohammed AhmedBolingbrook$1.1M
- Juan LermaEvergreen Park$351K
- Stuart SpragueEvanston$337K
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
- Omaima DeganiGurnee$184K
- Merry DownerSpringfield$156K
- Marco BonillaChicago$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.